A phase 3, randomized, placebo-controlled trial of filgrastim in patients with haematological malignancies undergoing matched-related allogeneic bone marrow transplantation

Archives of Drug Information

Volumn 1, Issue 3, 2008, Pages 89-96

  Ernst, Peter ^a   Bacigalupo, Andrea ^b   Ringdén, Olle ^c   Ruutu, Tapani ^d   Kolb, Hans J ^e   Lawrinson, Susan ^f   Skacel, Tomas ^g,h  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b Centro Trapianti di Midollo Osseo   (Italy)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f AMGEN LTD   (United Kingdom)

^g AMGEN INC   (United States)

^h UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Allogeneic Bone Marrow Transplant; Filgrastim; Graft versus Host Disease; Neutrophils; Randomized Clinical Trial; Survival

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; KIDNEY DYSFUNCTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTE COUNT; WEIGHT CHANGE;

EID: 77952096664     PISSN: None     EISSN: 17535174     Source Type: Journal    
DOI: 10.1111/j.1753-5174.2008.00013.x     Document Type: Article

References (15)

1. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with Chronic myeloid leukaemia before allogeneic Blood or Marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow transplantation. Lancet 1998; 352: 1087-92.
2. Schriber JR, Chao NJ, Long GD, Negrin RS, Tierney DK, Kusnierz-Glaz C, et al. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood 1994; 84: 1680-4.
3. Berger C, Bertz H, Schmoor C, Behringer D, Potthoff K, Mertelsmann R, et al. Influence of recombinant human granulocyte colony-stimulating factor (Filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors. Bone Marrow Transplant 1999; 23: 983-90.
4. Bishop MR, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Pavletic ZS, et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000; 96: 80-5.
5. Przepiorka D, Smith TL, Folloder J, Anderlini P, Chan KW, Korbling M, et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 2001; 97: 3405-10.
6. Ozcan M, Ustün C, Akçaǧlayan E, Akan H, Arslan O, Illhan O, et al. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 27: 499-505.
7. Khoury HJ, Loberiza FR, Ringden O, Barrett AJ, Bolwell BJ, Cahn J-Y, et al. Impact of post-transplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Transplantation 2006; 107: 1712-16.
8. Singhal S, Powles R, Treleaven J, Horton C, Mehta J. Long-term safety of GM-CSF (molgramostim) administration after allogeneic bone marrow transplantation for hematologic malignancies: Five-year follow-up of a double-blind randomized placebo-controlled study. Leuk Lymphoma 1997; 24: 301-7.
9. Appelbaum FR. Use of granulocyte colony-stimulating factor following hematopoietic cell transplantation: Does haste make waste? J Clin Oncol 2004; 22: 390-1.
10. Ringden O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: A study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22: 416-23.
11. Mehta J. Myeloid growth factors should not be administered routinely after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol 2004; 22: 4429-30; author reply 4430-2.
12. Remberger M, Naseh N, Aschan J, Barkholt L, LeBlanc K, Svennberg P, et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transpl 2003; 32: 217-23.
13. Ho VT, Mirza NQ, Junco DD, Okamura T, Przepiorka D. The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: A meta-analysis. Bone Marrow Transpl 2003; 32: 771-5.
14. Dekker A, Bulley S, Beyene J, Depuis L, Doyle JJ, Sung L. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006; 24: 5207-15.
15. Frassoni F, Sessarego M, Bacigalupo A, Strada P, Repetto M, Micelli S, etal. Competition between recipient and donor cells after bone marrow transplantation for chronic myeloid leukaemia. Br J Haematol 1988; 69: 471-5.